<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896662</url>
  </required_header>
  <id_info>
    <org_study_id>VICC PHI 0433</org_study_id>
    <secondary_id>VU-VICC-PHI-0433</secondary_id>
    <secondary_id>VU-IRB-040852</secondary_id>
    <nct_id>NCT00896662</nct_id>
  </id_info>
  <brief_title>Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202</brief_title>
  <official_title>Analysis of Dendritic Phenotype and Function of Patients Receiving VEGF-Trap on VGFT-ST-0202</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Studying the dendritic cells in samples of blood from patients with cancer
      receiving aflibercept may help doctors learn about the effect of aflibercept on dendritic
      cells.

      PURPOSE: This laboratory study is evaluating dendritic cells in patients with advanced solid
      tumors or non-Hodgkin lymphoma receiving aflibercept on clinical trial VGFT-ST-0202.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the effect of in vivo aflibercept on the presence of different populations of
           dendritic cells (DC) and immature cells (ImC) in the peripheral blood of cancer patients
           by characterizing the time course (kinetics) of the improvement in antigen presenting
           cell (APC) phenotype (decline in DC/ImC ratio) occurring early and late after
           aflibercept administration.

        -  Evaluate the effect of aflibercept administration on DC function based on ability to
           stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic T
           cell responses (influenza) by characterizing the time course (kinetics) of the
           improvement in APC function occurring early and late after aflibercept administration.

        -  Explore the relationship of baseline aflibercept level and host APC phenotype.

      OUTLINE: This is a multicenter study.

      Patients undergo phlebotomy and blood collection at baseline and on days 15, 29, and 57.
      Samples are analyzed for dendritic cell phenotype, subpopulations, maturation status, and
      function in terms of ability to activate autologous T cells.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of in vivo aflibercept on the presence of different populations of dendritic cells (DC) and immature cells (ImC)</measure>
    <time_frame>at days 15, 29 and 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of aflibercept administration on DC function based on ability to stimulate antigen specific proliferative (allogeneic and tetanus toxoid) and cytolytic T cell responses (influenza)</measure>
    <time_frame>at days 15, 29 and 64</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of aflibercept level with host antigen presenting cell phenotype at baseline</measure>
    <time_frame>at days 15, 29 and 64</time_frame>
  </primary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Lymphoma</condition>
  <condition>Solid Tumor</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
    <description>immunologic technique</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>laboratory biomarker analysis</description>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>pharmacological study</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      50cc of peripheral blood will be collected in CPT tubes for mononuclear cell isolation and
      10cc in SST tubes for plasma collection.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Up to 25 patients; three at each dose level achieved in order to gain additional
        information regarding safety, pharmacokinetics, and biological effect of VEGF Trap given
        intravenously.

        Patients with a solid tumor and is consented and eligible for enrollment onto VGFT-ST-0202.
        Patients who are willing to undergo phlebotomy prior to treatment, and 14 and 28 and 57
        days following initial dose of VEGF-Trap. Patients with an Hgb ≥10gm at the time of blood
        draw.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of advanced solid tumor or non-Hodgkin lymphoma and enrolled on clinical
             trial VGFT-ST-0202

          -  Hemoglobin ≥ 10 g/dL

          -  Willing to undergo phlebotomy

        Exclusion Criteria:

          -  none listed

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey A. Sosman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>April 21, 2016</last_update_submitted>
  <last_update_submitted_qc>April 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Jeffrey A. Sosman, MD</investigator_full_name>
    <investigator_title>Professor of Medicine, Medical Oncologist</investigator_title>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

